Trial Search Results

A Study of Modified Stem Cells in Stable Ischemic Stroke

The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and and with no further improvement from physical therapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

SanBio, Inc.

Stanford Investigator(s):


  • Biological: SB623


Phase 1/Phase 2


Inclusion Criteria:

   - Documented history of one completed ischemic stroke in subcortical region of MCA or
   lenticulostriate artery with or without cortical involvement

   - Between 6 and 60 months post-stroke, and having a motor neurological deficit

   - No significant further improvement with physical therapy/rehabilitation

   - Able and willing to undergo computed tomography (CT), magnetic resonance imaging
   (MRI), and positron-emission tomography (PET) scans of the head

Exclusion Criteria:

   - History of more than 1 symptomatic stroke

   - History of seizures

   - History or presence of any other major neurological disease

   - Myocardial infarction within prior 6 mos.

   - Known presence of any malignancy except squamous or basal cell carcinoma of the skin

   - Participation in any other investigational trial within 4 weeks of initial screening
   and within 7 weeks of study entry

   - Contraindications to head CT, MRI, or PET

   - Pregnant or lactating

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Coburn
Not Recruiting